Our team of specialized thinkers design and execute strategic communications programs that make our clients’ technologies, products, and services known, understandable, and approachable.

www.lavoiehealthscience.com

DOMAIN EXPERTISE

• RARE DISEASE • CAR-T • GENE THERAPY AND GENETIC THERAPEUTICS • IMMUNO-ONCOLOGY • ONCOLOGY • CNS • NEURODEGENERATION • MED TECH & DEVICES

• OPHTHALMOLOGY • PRECISION MEDICINE • RNA • AUTOIMMUNE DISEASES • CELL THERAPY • CRISPR • REGENERATIVE MEDICINE • LYSOSOMAL DISEASES

We help our clients extend visibility and optimize value for their

technologies, products, and services. INTEGRATED COMMUNICATIONS • Strategy Consulting • Investor Relations & Corporate Communications • Public Relations & Marketing HIGH-TOUCH, AWARD WINNING AGENCY • Specialized expertise in health and science innovations • 360° approach to media relations, social/digital, in-person events & presentations • Certified in healthcare communications compliance • Top 25 independent healthcare communications agency (O’Dwyers 2020) • 50+ awards • Two decades in business • Boston Business Journal’s The List: Largest PR Firms in Mass. • INC. 5000 Hall of Fame - Fastest Growing Private Companies • Donna LaVoie named to PharmaVOICE 100 most inspiring people in the life sciences industry • PR News’ Agency Elite 100 • 2020 PharmaVOICE 100 Award to Donna LaVoie GLOBAL REACH AND SCALE IN HEALTH Through our alliance with the DAS Group of Companies, a division of Omnicom Group, Inc. (NYSE:OMC), LaVoieHealthScience provides its clients with extended reach and global capabilities.

This alliance was cemented by the two parties so that LaVoieHealthScience can remain true to its innovative company client base, solving complex communications challenges and extending reach of its clients, while offering additional thinking and opening key markets to them as they develop and grow their companies. STRATEGIC VALUATION ASSESSMENT LaVoieHealthScience and Bioscience Valuation BSV GmbH (“BSV”) announced a strategic alliance between the two firms in June 2020. The alliance combines LHS’ expertise in strategic communications for companies at the forefront of health and science innovation with BSV’s skill in providing strategic valuation assessments for life science companies.

1

2

Marke

ting

an

d Digital Commun

icat

ion

s

Inte

grat

ed Co

rporate Communications

Investor RelationsPu

blic R

elat

ions

Publ

ic R

elation

s

He

alth Science Experience S

trateg

ic C

ouns

el

Personalized ServiceSol

id E

xecu

tion

Health ScienceCommunications

INTEGRATED COMMUNICATIONS

Our vision is to provide the very best strategic, integrated communications to health and science clients worldwide by leveraging our strategic relationships, and providing industry-tested pragmatic counsel and execution.

Proven Methodologies Through our trademarked methodologies, LHS provides its clients with a proven process for establishing its foundational positioning and messaging (The LHS Immersion®) and blueprint plan, all aligned to key stakeholders. The positioning is supported by LHS message testing and development of a strategic communications plan. Our LHS Fifteen-Slide Presentation® provides a foundational set of slides for telling your company’s story based on 15 core concepts.

3

INTEGRATED COMMUNICATIONS

Strategy Consulting • LHS Immersion® positioning and messaging

(programs for established and emerging companies) • The LHS Fifteen-Slide Presentation® • The LHS Message Testing™ • Partnering and licensing representation • Market research • Crisis planning and execution Investor Relations & Corporate Communications • IPO communication planning & execution • Strategic counsel • LHS Reach™ targeting • M&A communications • IR analyst relations • Perception audit • Analyst days and KOL events • Meeting management • Investor outreach • Virtual meetings with investors and analysts • Crisis prevention and communications • Virtual roadshows & summits • Retail programs Public Relations & Marketing • PR strategy and execution • Health and disease awareness • Media relations • Executive visibility • Speaker/media training • Advocacy relations • Event/meeting planning • Access to partnering and financing opportunities • Social media content, development and analytics • Pre/post commercialization • Corporate materials • Corporate and branding visual identity • Digital influence and new media • Internal communications • Thought leadership • Advocacy relations • Issues/reputation management • Content development • Analytics • Video, web development & SEO • Crisis prevention and management

4

CASE STUDIES

Results • Increased awareness and understanding of company's value proposition • Developed new corporate communications assets including a corporate

profile video and investor presentation • Secured high profile institutional analyst coverage and created and

distributed 20 corporate and financial disclosures released within 3 months

• Coordinated more than 50 initial high-value 1-on-1 meetings with investors and potential business partners, and arranged high visibility broadcast interviews with key reporters to further TFF leadership profiles

Our health science expertise uniquely positions us to help clients make their innovations known, understandable, and approachable to target audiences

through carefully executed strategies and plans.

INVESTOR RELATIONS

Challenge • Build investor relations credibility and

visibility for a recently public NASDAQ company with a novel technology for inhalant therapeutics to solve a major drug delivery challenge

LaVoieHealthScience Solution • Implemented the LHS Immersion®

and blueprint planning process to discover key messages and define visibility strategies

• Develop a “full charge” investor relations infrastructure program based on best practices to ensure disclosure, transparency, and investor confidence

• Use LHS Reach™ to aggressively extend company outreach within the institutional investment community

• Leverage LHS’ extensive capital markets access to introduce management to key analysts and bankers

5

Challenges • International company on NASDAQ with broad

pipeline in neurodegenerative diseases • Impacted by recent industry trial failures in

Alzheimer’s disease • Seeking to raise visibility as a thought leader in

neurodegenerative area • Create visibility in national, business and trade

publications in U.S. market LaVoieHealthScience Solution • Increase brand awareness throughout the U.S.,

aiming for high profile media outlets while building and cementing relationships with top journalists

• Position CEO as a major thought leader/expert in the neurodegenerative disease area

• Differentiate from competitors in the marketplace through careful, artful message crafting

PUBLIC & MEDIA RELATIONS

Results • Cohesive integrated communication strategy

plan with flawless execution • ~100 pieces of media – U.S. • Top mentions and original posts/ articles in

Forbes, Reuters, PharmaVoice, Endpoints, FierceBiotech, In Vivo, BioWorld, Life Science Leader, BioSpace and STAT

• Two thought leadership opinion/expert articles focused on the future of AD

6

STRATEGIC COMMUNICATIONS & CORPORATE DEVELOPMENT

Challenge • Build awareness for a European

gene therapy viral vector technologies company targeting U.S. drug developers and investors

LaVoieHealthScience Solution • Revised messages, brand image &

corporate materials • Created an investor presentation

based on the LHS 15 Slide Presentation® methodology

• Identified and conducted outreach to gene therapy developers

• Managed and supported SIRION Biotech roadshow and overall awareness campaign

• Drove awareness through increased news flow planning and media outreach

• Developed social media strategy and monthly planning calendar

Results • 11 license agreements signed, LHS assisted with the first • U.S. revenue as percentage of total revenue increased from 6%

in 2012 to 67% in 2019 • Company revenue increased from approx. $648k in 2012 to

approx. $11M in 2019 • Established company as a high value partner with

differentiated value proposition • Increased social media presence with strategic planning and

content • Developed awareness and relationships with U.S. media

7

PUBLIC RELATIONS

Results • Secured 13 one-on-one interviews with

leading publications • 12 original articles and 1 podcast were

written on the launch with 100% positive sentiment and on target messaging

• Press release received 6,370+ views, generated 54 syndicated articles and 172 pickups.

• Total program included 46.8 M earned impressions

• Won Silver Bell Ringer award for Media Placements Digital/Print Series

Challenges • Xontogeny and Perceptive Advisors formed a

new VC fund known as the Perceptive Xontogeny Venture (PXV) Fund

• Build recognition of the PXV Fund brand and the differentiated Xontogeny model

• Maximize impact with business and industry press LaVoieHealthScience Solution • Create positioning and messaging for the PXV

Fund that differentiated it from other traditional early-stage VCs

• Developed high impact press release and media outreach strategy including non-exclusive, embargoed access for highly desired media outlets

• Pitched fund announcement to important media targets and many “out of the box” outlets

• Included limited access interviews for key Perceptive Advisors team members

• Thought leadership series across targeting platforms

8

Val Kennedy CONTENT EDITOR/ STRATEGIST

Results • On-message coverage in relevant publications including:

Medgadget, Proactive Investors, Interventional News, and Drug Delivery Business

• Twitter ad generated 8,076 impressions and 71 engagements • 40 attendees at satellite session on TPT payment status at SIO

conference • Advertorial placed in Interventional News (12,200 subscribed

readers) and 27,000+ views on website • Placed CEO as panelist at BIO CEO & Investor Conference • Won Bronze Bell Ringer award for Healthcare Launch Campaign

Challenges • Launch of a new drug delivery device which

received highly coveted transitional pass-through payment (TPT) status from the Centers for Medicare and Medicaid Services (CMS)

• Lack of understanding of the benefits of the TPT process among key stakeholder audiences

LaVoieHealthScience Solution • Create differentiated positioning and messaging

for the launch and promote via media outreach • Educate key stakeholders with earned and paid

approach on the unique advantages of TriNav system and its elite CMS TPT status

• Utilize medical meetings to promote awareness with media and Interventional Radiologists

• Develop Twitter ad using geotargeting around Society of Interventional Oncology (SIO) conference

• Identified relevant advertorial opportunities

NEW PRODUCT LAUNCH

Meet the Senior Team

Sharon Correia EXECUTIVE VICE PRESIDENT & CHIEF STRATEGY OFFICER

Lisa DeScenza VICE PRESIDENT, INTEGRATED COMMUNICATIONS

Ella Deych Cerminara VICE PRESIDENT, FINANCE & CHIEF OPERATIONS OFFICER

Sharon Choe SENIOR VICE PRESIDENT, INVESTOR RELATIONS & BUSINESS DEVELOPMENT

Paul Sagan VICE PRESIDENT, INVESTOR RELATIONS & CORPORATE COMMUNICATIONS

Barrett McGrath SENIOR BUSINESS DEVELOPMENT ADVISOR

Val Kennedy CONTENT EDITOR/ STRATEGIST

Katie Gallagher ACCOUNT DIRECTOR, PR & MARKETING

Brian Pinkston ACCOUNT DIRECTOR, INVESTOR RELATIONS & CORPORATE COMMUNICATIONS

Donna LaVoie PRESIDENT & CEO

Douglas Russell SENIOR VICE PRESIDENT, CLIENT SERVICES & PR/ MEDIA

Harriet Ullman ASSISTANT VICE PRESIDENT, PR & PRODUCT COMMUNICATIONS

Dionne Daley EXECUTIVE ASSISTANT

Emmie Twombly MEDIA RELATIONS SPECIALIST

UPDATED 10/20

Deanna Meservey ASSISTANT VICE PRESIDENT, COMMUNICATIONS, PR & MEDIA

www.lavoiehealthscience.com

Agency Headquarters 20 Park Plaza, Suite 312 Boston, MA 02116 New York Region 857.241.7393 South Florida Region 617.865.5557

Email: info@lavoiehealthscience.com

https://www.linkedin.com/company/lavoie-group

@lavoiegroup

https://www.facebook.com/LaVoieGroup/

Global Alliance with OmnicomPublicRelationsGroup